-
Article
From macroprolactinoma to concomitant ACTH-PRL hypersecretion with Cushing’s disease
Multiple pituitary hormone hypersecretions have been already described, but the combination of PRL and ACTH excess is rare. This report deals with a 42-yr-old woman affected by macroprolactinoma (PRL 12,720 μg...
-
Article
Scintigraphic imaging of pituitary adenomas: An in vivo evaluation of somatostatin receptors
We have performed pituitary scintigraphy with the somatostatin (SS) analog pentetreotidean by (111In-P) in patients with GH-secreting adenoma or with “clinically non functioning” adenoma (NFA) to evaluate the pre...
-
Article
Effects of tamoxifen on GH and IGF-I levels in acromegaly
Tamoxifen (TAM), a non steroid partially competitive antagonist to the estrogen receptors, has been reported to decrease plasma GH and IGF-I levels both in vitro and in vivo. These data prompted us to evaluate GH...
-
Chapter
Endocrine Tests and Hormonal Therapy in Craniopharyngioma
The hypothalamus exerts control over the anterior pituitary gland and synthesizes hormones of the posterior pituitary: vasopressin and oxytocin are synthesized in the hypothalamic-supraoptic and paraventricula...
-
Article
Doxorubicine for acromegaly: a case report
We report the case of an acromegalic woman, aged 35 years, with a huge GH-secreting tumor, repeatedly treated with neurosurgery and radiotherapy, not responsive to bromocriptine (Br) and octreotide (SMS), whos...
-
Article
Prolactin response to growth hormone-releasing hormone during chronic thyrotropin-releasing hormone infusion in the treatment of amyotrophic lateral sclerosis
In six patients suffering from amyotrophic lateral sclerosis we evaluated changes of T4, T3, TSH, PRL, and GH during treatment by continuous iv infusion of TRH for at least 15 days. No clinical improvement was...
-
Article
Resistance to a long-acting somatostatin analog (SMS 201-995) reversed by surgery in acromegaly
A 42-year-old woman had acromegaly and a large macroadenoma with supra- and parasellar extension. Her GH levels (median 85 ng/ml, range 63–170 ng/ml) were not responsive to TRH (200 μg iv), GHRH (100 μg iv) an...
-
Chapter and Conference Paper
Medical treatment of acromegaly — Dopa-minergic agonists and long-acting somatostatin
The medical treatment of acromegaly derives its values from the fact that neurosurgey and radiation therapy may be, in this disease, frequently unsuccessful. Indeed, the frequency with which neurosurgery cures...
-
Article
Clinical use of the somatostatin analog SMS 201–995 in endocrinology
-
Chapter and Conference Paper
Medical Treatment of Acromegaly. Dopaminergic Agonists and Long-Acting Somatostatin
The medical treatment of acromegaly is of value because neurosurgery and Rx therapy may be unsuccessful in this disease.
-
Article
Medical treatment of pituitary adenomas: effects on tumor growth
-
Article
Effect of chronic bromocriptine administration on tumor size in patients with “nonsecreting” pituitary adenomas
The effect of chronic bromocriptine administration (7.5–20 mg/day for 1 -32 months) on the size of “nonsecreting” pituitary adenomas (NPA) was studied in 20 patients. Brain computed tomography showed a marked ...
-
Article
Cushing’s disease and marked hyperprolactinemia in a patient with a pituitary macroadenoma: effectiveness of bromocriptine treatment
The case of a young boy bearing a pituitary PRL secreting adenoma (20–30,000 ng/ml) with the unusual association of clinical and endocrinological features of Cushing’s disease successfully treated with bromocr...
-
Article
Macroprolactinomas: CT evaluation of reduction of tumor size after medical treatment
Thirty patients with macroprolactinomas were treated with dopaminergic drugs from a minimum of 4 months to a maximum of 6 years. Tumor size was evaluated with serial CT during treatment; serum prolactin levels...
